Abciximab
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
tositumomab
radioimmunoconjugate, anti-CD20, 131I · anticancer
radioimmunoconjugate, anti-CD20, 131Ianticancer
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AdalimumabSevereDatabaseDDInter
- AlteplaseSevereDatabaseDDInter
Mechanism
Tositumomab provides targeted delivery of radionuclides to tumor cells through a murine monoclonal antibody against CD20 conjugated with 131Iodine.
Indications
relapsed lymphoma
Side effects
Serious
- antibody-related hypersensitivity
- bone marrow suppression
- secondary leukemias
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alteplase
Severe
Database
Clinical effect not specified
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Antithrombin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Iii Human
Severe
Database
Clinical effect not specified
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Argatroban
Severe
Database
Clinical effect not specified
Source: DDInter
Aspirin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ask House about tositumomab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team